Little Analysis Bud, $5 on the bid, held for 30 days or more changes the entire investment picture. It would no longer be deemed a penny stock under the SEC definitions. Also, most blue-chip firms cannot invest in stocks under $5.00 because their buy-laws prohibit such investment practices, and that itself, could be a reason why NITE won't let it run. I think for a pre-revenue company, $15 PPS ($17.5M) market cap is reasonable albeit, maybe still a bit underpriced for a medical/healthcare technology company.
I think if the price goes to $25.00 sooner than later, the company may ask those insider preferrers to convert some of those shares into common in order to increase market cap keeping the stock price manageable, which is another requirement for uplisting to either NASDAQ or NYSE-MKT. And that wouldn't be a bad thing either, because even if they converted say an aggregate of 4 million shares, it would only bring the outstanding to 5.4M shares, and if falls back to $10 trading PPS, that would still be a $54M market cap. If the stock maintains $20 PPS, its over a $100M market cap. Plus those shares wouldn't hit the market for at minimum 6 months, and afterwards would all be subject to Rule 144 sales limitations anyway, and by that time, maybe the company would do a SPO in simultaneously with an uplist. It would also provide potential financing investors an eye to future liquidity, if they are concerned about that.